CNSide Diagnostics logo
Order a Test

Pharmafile Interview with CNSide President Russell Bradley

by | Aug 16, 2025 | News

Expert Insights on CNS Metastases

Russell Bradley, President and General Manager of CNSide Diagnostics, recently sat down with Pharmafile to discuss one of oncology’s greatest challenges: central nervous system (CNS) cancer metastases.

CNS metastases, including leptomeningeal metastases (LM), are notoriously difficult to detect and monitor with traditional methods. In the interview, Bradley highlights how innovative diagnostic technologies like the CNSide® CSF assay platform are helping transform the way clinicians approach diagnosis, disease monitoring, and treatment planning.

The Future of CNS Cancer Diagnostics

Bradley emphasized several key areas shaping the future of CNS cancer care:

  • Improved sensitivity in detecting CNS metastases compared to traditional cytology
  • Longitudinal monitoring to track disease progression and treatment response
  • Personalized medicine approaches that provide oncologists with real-time, actionable insights

Learn more about our CNSide CSF assay platform.

CNSide’s Mission

At CNSide Diagnostics, we’re committed to improving patient outcomes by developing cutting-edge cancer diagnostics. Our platform is designed to close critical gaps in early detection, monitoring, and treatment guidance for patients with CNS cancers.

#CNSide #CancerDiagnostics #CNSMetastases #NeuroOncology #PrecisionMedicine #LeptomeningealMetastases #BrainCancer #CancerResearch #OncologyInnovation

Written By CNSide Diagnostics

undefined
More Posts by CNSide

Related Posts

Two New Strategic Executive Hires

Dec 9, 2025 |

Expanding operational and regulatory expertise to support commercialization and growth Plus Therapeutics (NASDAQ: PSTV) today announced two key leadership additions to CNSide Diagnostics, its wholly-owned subsidiary, further strengthening the company’s operational...

read more

Houston Business Journal

Dec 5, 2025 |

Strengthening CNS oncology diagnostics at the heart of America’s largest medical ecosystem CNSide Diagnostics, a subsidiary of Plus Therapeutics (NASDAQ: PSTV), has officially expanded into Levit Green, a premier life sciences innovation campus developed by Hines in...

read more

0 Comments